Healthcare / Drug Manufacturers - Specialty & GenericTaiwan
$61.60
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.0B
P/E
11.9x
↓EV/EBITDA
5.3x
↓ROE
15.1%
↑Gross Margin
41.4%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.3%
FCF CAGR
+246.8%
FCF margin
18.0%
FCF / Net income
1.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.02B · net income $927.7M · FCF $1.26B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.02B | $7.02B | $6.79B | $6.24B | $5.85B |
| Net Income | $927.7M | $927.7M | $880.5M | $834.9M | $815.4M |
| EBITDA | $1.96B | $1.96B | $2.05B | $1.81B | $1.72B |
| EPS | — | — | 4.92 | 4.67 | 4.56 |
| Gross Margin | 41.4% | 41.4% | 44.0% | 43.7% | 42.5% |
| Operating Margin | 19.4% | 19.4% | 20.7% | 20.0% | 19.4% |
| Net Margin | 13.2% | 13.2% | 13.0% | 13.4% | 13.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.16 | 0.32 | 0.47 |
| Current Ratio | 2.04 | 2.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.26B | $1.26B | $1.10B | $708.5M | $30.3M |
| Returns | |||||
| ROE | 15.1% | 15.1% | 14.9% | 15.8% | 17.2% |
| Valuation | |||||
| P/E | 11.89 | 11.89 | 12.46 | 14.24 | 12.68 |
| EV/EBITDA | 5.27 | 5.27 | 5.06 | 6.38 | 6.01 |
| P/B | 1.80 | 1.80 | 1.86 | 2.24 | 2.18 |
| Growth & Yield | |||||
| Revenue Growth | 3.4% | 3.4% | 8.8% | 6.6% | — |
| EPS Growth | — | — | 5.4% | 2.4% | — |
| Dividend Yield | 4.6% | 4.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.6%
Start / end P/E
n/dx → n/dx
EPS bridge
4.92 → n/d
Residual
+4.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.